Evidence map›Paper›PMID 34442385›Full record

ArticleJournal of personalized medicine2021

Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?

Katherine Hicks-Courant, Jenny Shen, Angela Stroupe, Angel Cronin, Elizabeth F Bair, Sam E Wing, Ernesto Sosa, Rebekah H Nagler, Stacy W Gray

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Katherine Hicks-CourantDivision of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jenny ShenDepartment of Psychology, The State University of New York at Stony Brook, Stony Brook, NY 11794, USA.
Angela StroupePatient Reported Outcomes, Pharmerit International, Cambridge, MA 02142, USA.
Angel CroninCorrona, LLC., Waltham, MA 02451, USA.
Elizabeth F BairDepartment of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sam E WingDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Ernesto SosaDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Rebekah H NaglerHubbard School of Journalism & Mass Communication, University of Minnesota, Minneapolis, MN 55455, USA.
Stacy W GrayDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
City of Hope · USUniversity of Pennsylvania · USPharmerit (United States) · USState University of New York · USUniversity of Minnesota · US

Funding

American Cancer Society 120529-MRSG-11-006-01-CPPB
6 · The paper itself

Abstract

backgroundGiven that media coverage can shape healthcare expectations, it is essential that we understand how the media frames "personalized medicine" (PM) in oncology, and whether information about unproven technologies is widely disseminated.

methodsWe conducted a content analysis of 396 news reports related to cancer and PM published between 1 January 1998 and 31 December 2011. Two coders independently coded all the reports using a pre-defined framework. Determination of coverage of "standard" and "non-standard" therapies and tests was made by comparing the media print/broadcast date to the date of Federal Drug Administration approval or incorporation into clinical guidelines.

resultsAlthough the term "personalized medicine" appeared in all reports, it was clearly defined only 27% of the time. Stories more frequently reported PM benefits than challenges (96% vs. 48%,

conclusionConfusion about personalized cancer medicine may be exacerbated by media reports that fail to clearly define the term. While most media stories reported on standard tests and treatments, an emphasis on the benefits of PM may lead to unrealistic expectations for cancer genomic care.

Indexed as

genomic testingnews mediapersonalized medicinepublic awarenesstargeted therapies

Identifiers

PMID34442385
PMCPMC8399271
OpenAlexW3185984670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.